openPR Logo
Press release

Janssen Biotech, Inc. "REMICADE" Market size expansion of Several Folds by 2032

03-27-2024 07:26 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Janssen Biotech, Inc. "REMICADE" Market size expansion

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on REMICADE (Janssen Biotech, Inc.) providing insights into the drug market landscape and market forecast of REMICADE upto 2032. The report, titled "REMICADE Market Market Size, Forecast, and Drug Insight - 2032" is now available for review and analysis.

Are you interested in finding out the projected market size of REMICADE in 2032? REMICADE Market Forecast
https://www.delveinsight.com/report-store/remicade-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

The REMICADE Market Report offers projected sales forecasts for REMICADE for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Janssen Biotech, Inc.'s REMICADE is serving as a beacon of hope for the patients suffering from Ulcerative Colitis.

What is a REMICADE Prescribed for?
Janssen Biotech, Inc.'s REMICADE® is approved for reducing both the signs and symptoms and for initiating and sustaining clinical remission in adult patients diagnosed with moderately to severely active Ulcerative Colitis who have not responded adequately to conventional therapy.

The report extensively covers the details and developments related to REMICADE, capturing important highlights on developmental pipeline, regulatory status and special designations of REMICADE, route of administration, safety and efficacy details.

REMICADE Market Assessment
This report provides a detailed market assessment of REMICADE for Ulcerative Colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

REMICADE Clinical Assessment
The report provides the clinical trials information of REMICADE for Ulcerative Colitis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against REMICADE? REMICADE Drugs Insights
https://www.delveinsight.com/sample-request/remicade-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

REMICADE Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the REMICADE.

REMICADE Market Size in the US
A dedicated section of the report focuses on the expected market size of REMICADE for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of REMICADE:

• The report contains forecasted sales of REMICADE for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Ulcerative Colitis.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for REMICADE in Ulcerative Colitis.
Stay ahead in competition by leveraging insights on REMICADE market Report: Download REMICADE Market Report
https://www.delveinsight.com/sample-request/remicade-market-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy REMICADE Market Report:
• The report provides future market assessments for REMICADE for Ulcerative Colitis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading REMICADE for Ulcerative Colitis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REMICADE
• Discover the competitive landscape of REMICADE through 7MM
• Get a Thorough Analysis of the REMICADE Development pipeline, Safety & Efficacy of the REMICADE, and ROA
• Thorough REMICADE market forecast will help understand how drug is competing with other emerging REMICADE
• Get analysis of the REMICADE clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Ulcerative Colitis Pipeline https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Ulcerative Colitis Pipeline Insight, 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The Ulcerative Colitis companies in the market inlcude - Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, Anaptys Bio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellael, Palatin Technologies, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Latest Report Offered By DelveInsight:

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Janssen Biotech, Inc. "REMICADE" Market size expansion of Several Folds by 2032 here

News-ID: 3444297 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for REMICADE

Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025? In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic
Remicade Biosimilar Market Size, Trends, Analysis And Forecast 2024-2033
"The Business Research Company recently released a comprehensive report on the Global Remicade Biosimilar Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample
Affordable Innovation: 2024 Global Market Report on Remicade Biosimilars
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Remicade Biosimilar Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $9.1 billion In 2028 At
Remicade Biosimilar Market Size & Growth Analysis Report, 2021-2027
Biosimilar can be defined as a type of biological product that is highly similar to an already FDA approved drug, known as reference biological product. (Get 15% Discount on Buying this Report) Get Sample Copy of Remicade Biosimilar Market at: https://www.orionmarketreports.com/remicade-biosimilar-2-market/48410/#ert_pane1-1 Segment by Type • 100mg/10ml • 500mg/50ml Segment by Application • Blood Disorders • Oncology Diseases By Company • Synthon Pharmaceuticals • LG Life Sciences • Novartis (Sandoz) • Celltrion • Biocon • Hospira • Merck Serono (Merck Group) • Biogen idec Inc A full report of Global Remicade Biosimilar Market is available at: https://www.orionmarketreports.com/remicade-biosimilar-2-market/48410/ Scope of the Report The research
Biosimilar of Remicade Market Is Thriving Worldwide
In a recent S&R Research publish Global Biosimilar of Remicade Market Insights, Forecast to 2025, analysts provide an in-depth analysis of the global market for Biosimilar of Remicade. By analyzing its historical and forecast data, the analysis analyzes the different aspects of the market. Some are part of the coverage and are the core and emerging players being profiled Synthon Pharmaceuticals, LG Life Sciences, Novartis (Sandoz), Celltrion, Biocon, Hospira, Merck
Remicade (Infliximab) Biosimilar Clinical Trial Insight
“Remicade (Infliximab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 17 biosimilar version of Remicade drug in clinical pipeline. Currently there are 2 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Remicade are commercially available in India, Brazil and European countries for the treatment of Ankylosing spondylitis, Crohn's disease and Rheumatoid Arthritis. The